The MHRA is surveying UK healthcare professionals to discover the best ways to keep patients informed when a drug’s risk profile changes.
The survey forms part of initiative, SCOPE - the Strengthening Collaboration for Operating Pharmacovigilance in Europe. SCOPE focuses on five specific pharmacovigilance work areas: adverse drug reaction (ADR) collection, signal management, risk communications, quality management systems (QMS) and lifecycle pharmacovigilance.
The intention of the survey is to find ways in which regulatory safety communication can be improved. The MHRA will be providing examples of the commonest forms of communication (like drug safety updates and educational materials) to try and assess which are read and acted upon.
The survey also aims to discover which media are preferred for different messages as well as gauging the value put on safety information on channels such as email, social media, text messages and websites.
Additionally, the survey asks respondents to quantify how likely they are to take action on a specific safety warning based on different criteria such as the seriousness of an ADR or the ease of implementing a recommendation.
The other side of the equation, how to communicate ADR data to regulatory authorities, is covered in some detail in module 1 of our 4-module pharmacovigilance course, Pharmacovigilance and Drug Safety
For more information on the MHRA survey, click [here].
How do YOU think patients should be told when the risk profile of their medication changes? It would be really interesting to know what you think....
|
|
 |
|
|
Share on LinkedIn |
Share via Email |
